FUNDAMENTALS · Fundamentals · CN Healthcare

Adagene (ADAG) Fundamentals 2026 — Revenue Analysis | SniperIQ

Adagene (ADAG) is a CN-listed Healthcare company in Biotechnology with a market capitalization of

35M, trading at
.58 on the NASDAQ. This SniperIQ fundamentals page covers Adagene's valuation, profitability (net margin -229.5%), revenue ($8M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
35M
Net Margin-229.5%
Revenue (FY25)$8M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Adagene's market cap?

Adagene (ADAG) has a market capitalization of approximately

35M, trading at
.58 on the NASDAQ. Market cap moves with the live share price.

What is Adagene's P/E ratio?

Adagene's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Adagene?

Adagene runs a net profit margin of -229.5%, a gross margin of 92.4%, and an operating margin of -279.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Adagene generate?

Adagene reported revenue of $8M for fiscal year 2025, with net income of -

8M and earnings per share (EPS) of -0.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Adagene pay a dividend?

Adagene does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Adagene financially healthy?

Adagene carries a debt-to-equity ratio of 0.18x and a current ratio of 3.07x, with a market beta of 0.58. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Adagene a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Adagene (ADAG) the key facts are: market cap

35M, revenue $8M, 52-week range 1.3-4.85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Adagene's full fundamentals live

Get Adagene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Lana Medical (9587) fundamentals · Aardvark Therapeutics, Inc. Common Stock (AARD) fundamentals · PepGen (PEPG) fundamentals · CVRx (CVRX) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons